longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Cafรฉ
longbridge
ยฉ 2026 Longbridge๏ฝœTerms of ServicePrivacy Policy

HIMZ

HIMZ
----

LongbridgeAI
H
Hardik Shah

Jun 11 at 03:25 PM

๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: Novo Nordisk's Wegovy Pill Approved in UK for Weight Management - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)

๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:

โžค UK approves ๐–๐ž๐ ๐จ๐ฏ๐ฒ ๐ฉ๐ข๐ฅ๐ฅ, oral semaglutide for weight management.

โžค UK becomes ๐„๐ฎ๐ซ๐จ๐ฉ๐ž'๐ฌ ๐Ÿ๐ข๐ซ๐ฌ๐ญ country authorizing the treatment.

โžค Approved for adults with ๐จ๐›๐ž๐ฌ๐ข๐ญ๐ฒ or weight-related conditions.

โžค Medication to be used alongside ๐๐ข๐ž๐ญ and ๐ž๐ฑ๐ž๐ซ๐œ๐ข๐ฌ๐ž.

โžค Novo expects availability via ๐ฉ๐ซ๐ข๐ฏ๐š๐ญ๐ž ๐ฉ๐ซ๐ž๐ฌ๐œ๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง within weeks.

โžค OASIS 4 trial: ๐š๐ฉ๐ฉ๐ซ๐จ๐ฑ๐ข๐ฆ๐š๐ญ๐ž๐ฅ๐ฒ ๐Ÿ๐Ÿ’% weight loss versus 2% placebo.

โžค Treatment-adherent participants achieved ๐š๐ฉ๐ฉ๐ซ๐จ๐ฑ๐ข๐ฆ๐š๐ญ๐ž๐ฅ๐ฒ ๐Ÿ๐Ÿ•% weight loss.

โžค Most common side effects were ๐ ๐š๐ฌ๐ญ๐ซ๐จ๐ข๐ง๐ญ๐ž๐ฌ๐ญ๐ข๐ง๐š๐ฅ symptoms.

โžค About ๐Ÿ•% discontinued treatment due to adverse events.

โžค Approval follows authorizations from ๐…๐ƒ๐€ and ๐”๐€๐„ regulators.

Novo Nordisk AS

Novo Nordisk AS

USNVO

Hims & Hers Health

Hims & Hers Health

USHIMS

Eli Lilly

Eli Lilly

USLLY

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.